EP Patent

EP2727590A1 — Compositions for treating centrally mediated nausea and vomiting

Assigned to Helsinn Healthcare SA · Expires 2014-05-07 · 12y expired

What this patent protects

Provided are orally administrable dosage forms for use in treating chemotherapy induced nausea and vomiting (CINV), radiation therapy induced nausea and vomiting (RINV), or post operative nausea and vomiting (PONV), comprising combination of palonosetron and netupitant.

USPTO Abstract

Provided are orally administrable dosage forms for use in treating chemotherapy induced nausea and vomiting (CINV), radiation therapy induced nausea and vomiting (RINV), or post operative nausea and vomiting (PONV), comprising combination of palonosetron and netupitant.

Drugs covered by this patent

Patent Metadata

Patent number
EP2727590A1
Jurisdiction
EP
Classification
—
Expires
2014-05-07
Drug substance claim
No
Drug product claim
No
Assignee
Helsinn Healthcare SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.